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Abstract
Vitamin D has a potential role in preventing HIV-related complications, based on its extensive involvement in
immune and metabolic function, including preventing osteoporosis and premature cardiovascular disease.
However, this association has not been examined in large studies or in resource-limited settings. Vitamin D
levels were assessed in 884 HIV-infected pregnant women at enrollment in a trial of multivitamin supple-
mentation (excluding vitamin D) in Tanzania. Information on HIV related complications was recorded during
follow-up (median, 70 months). Proportional hazards models and generalized estimating equations were used to
assess the relationship of vitamin D status with these outcomes. Women with low vitamin D status (serum 25-
hydroxyvitamin D < 32 ng/mL) had 43% higher risk of reaching a body mass index (BMI) less than 18 kg/m2
during the first 2 years of follow-up, compared to women with adequate vitamin D levels (hazard ratio [HR]:
1.43; 95% confidence intervals: [1.03–1.99]). The relationship between continuous vitamin D levels and risk of
BMI less than 18 kg/m2 during follow-up was inverse and linear ( p = 0.03). Women with low vitamin D levels
had significantly higher incidence of acute upper respiratory infections (HR: 1.27 [1.04–1.54]) and thrush (HR:
2.74 [1.29-5.83]) diagnosed during the first 2 years of follow-up. Low vitamin D status was a significant risk
factor for wasting and HIV-related complications such as thrush during follow-up in this prospective cohort in
Tanzania. If these protective associations are confirmed in randomized trials, vitamin D supplementation could
represent a simple and inexpensive method to improve health and quality of life of HIV-infected patients,
particularly in resource-limited settings.
Introduction
Progressive deterioration in immune function is themajor hallmark of HIV disease. Interventions such as vi-
tamin D supplementation, by virtue of their extensive in-
volvement in the human immune response,1 may help slow
HIV disease progression and improve quality of life in the
millions of HIV-infected individuals worldwide. In addition
to the regulation of calcium movement in gastrointestinal
mucosa, renal tubules, and the skeleton, vitaminD has several
other important metabolic functions.2 An increase in the oc-
currence of infections in children with rickets, the classic
vitamin D deficiency disease, has been reported although the
mechanisms implicated are not fully understood.3 Vitamin D
also has been shown to have an integral role in innate im-
munity and response to infections such as tuberculosis, one of
themost common opportunistic illnesses amongHIV-infected
individuals.4,5 Additionally, vitamin D supplementation can
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potentially help prevent or ameliorate the deleterious effects
of both the HIV infection and antiretroviral treatment on bone
mineral density and cardiovascular disease.6–8 Vitamin D can
improve insulin secretion and sensitivity, inhibit vascular
smooth cell proliferation, and downregulate the renin-
angiotensin system; these biologic actions may help explain
the potential benefits of vitamin D on metabolic disease.9–11
In recent work, we have shown that low vitamin D levels
(defined as serum 25-hydroxyvitamin D < 32 ng/mL) among
HIV-infected pregnant women at enrolment in a trial of vi-
tamin supplementation12 are associated with increased risks
of HIV disease progression, anemia, and mortality during
follow-up.13 In this article, we examined the relationship be-
tween low vitaminD status andHIV-related complications, as
it may provide an explanation for the increase in disease
progression andmortality amongwomenwith low vitamin D
status.
Methods
Study population
The study design has been previously described in detail.14
Briefly, participants were HIV-infected pregnant women en-
rolled in a randomized, double-blinded, placebo-controlled
trial of vitamin supplementation (1995–1997). Pregnant
women (12–27 weeks gestation) were randomized to receive
vitamin A alone, multivitamins (vitamins B-complex, C, and
E), both vitamin A and multivitamins, or placebo. All women
received iron-folate daily and chloroquine weekly as malaria
prophylaxis, according to national guidelines for antenatal
care at the time the trial was conducted. At the time of the
study, antiretroviral therapy (ART) was not available to most
women in Tanzania, including participants in the trial.
Informed consent was obtained from all participants.14 The
study protocol was approved by the Research and Publica-
tions Committee of the Muhimbili University College of
Health Sciences, the Ethical Committee of the National AIDS
Control Program of the TanzanianMinistry of Health, and the
Institutional Review Board of the Harvard School of Public
Health.
Assessment of baseline covariates
Structured interviews were conducted during the baseline
visit to collect information on demographic characteristics
including age, educational level, andmoney spent on food per
day. HIV disease stage was classified in accordance with
the World Health Organization (WHO) guidelines.15 Trained
research assistants obtained anthropometric measurements,
including height, weight, and mid–upper arm circumference,
using standardized procedures and calibrated instruments.
Assessment of outcomes
Women were followed through monthly study clinic visits,
and women who missed a clinic visit or traveled out of Dar es
Salaam were followed via a home visit. At each visit, physi-
cians performed a clinical examination, and a nurse assessed
self-reported symptoms and HIV-related complications in the
preceding period. HIV disease stage was assessed at each
visit, in accordance with WHO criteria.15 Height, weight, and
mid–upper arm circumference were also measured at each
visit.
Laboratory methods
Blood samples were obtained from study participants at
enrollment (12–27 weeks of gestation), and plasmawas stored
at or below - 70C. Vitamin D status was assessed using
serum levels of 25-hydroxyvitamin D [25(OH)D]. Serum
25(OH)D levels were measured by the fully automated che-
miluminescence ADVANTAGE 25(OH)D assay system
obtained from Nicholas Institute Diagnostics, San Juan
Capistrano, California. Absolute CD4, CD8, and CD3 T-cell
counts were evaluated with the FACSCount system (Becton-
Dickinson, San Jose, CA). Hemoglobin levels were assessed
using either a CBC5 Coulter Counter (Coulter Corporation,
Miami, FL) or by the cyanmethemoglobin method with use of
a colorimeter (Corning Inc., Corning, NY). HIV-1 serostatus
was determined by the Enzygnost anti-HIV-1/2 Plus assay
(Dade Behring, Germany) followed by theWellcozymeHIV-1
recombinant test (Murex Biotech Ltd., Dartford, UK). Dis-
cordant results were resolved via Western blot test (Bio-Rad
Laboratories Ltd., Hertfordshire, UK).16
Statistical analysis
Vitamin D status was defined as insufficient (<32 ng/mL
or <80 nmol/L) versus adequate. The cutoff of 32 ng/mL for
vitamin D insufficiency was based on requirements for opti-
mal calcium homeostasis17 and previous studies.18
Wasting was defined as a body mass index (BMI) of less
than 18 kg/m2; this is in accordance with our previous stud-
ies19 and was selected on the basis of findings from a study of
HIV-infected African adults demonstrating that BMI less than
18 kg/m2 had comparable validity as a CD4 T-cell count of
less than 200 cells per microliter in predicting mortality.20 We
also considered mid–upper arm circumference (MUAC) less
than 22 cm as an end point in this analysis in accordance with
the value recommended for screening for malnutrition in
women.21 Weight loss of more than 10% was also used as an
end point based on the conventional definition of HIV-related
wasting.22,23
We examined the relationship of vitamin D status at base-
line with wasting outcomes using proportional hazards
models.24 We examined the times to first episode of wasting
as defined by a BMI of less than 18 kg/m2, MUAC of less than
22 cm, and a weight loss of greater than 10% during follow-
up. For those without the outcomes, follow-up ended on the
date on which they were last assessed.
We investigated potential nonlinear relationship of con-
tinuous vitamin D levels with the risk of wasting outcomes
nonparametrically with stepwise restricted cubic splines.25,26
Tests for nonlinearity used the likelihood ratio test, comparing
the model with only the linear term to the model with the
linear and the cubic spline term.
The relationship between vitamin D levels and clinical
signs and symptoms including ulcers in themouth and throat,
painful tongue or mouth, difficult or painful swallowing,
nausea and vomiting, diarrhea, dysentery, fatigue, and rash
was analyzed using generalized estimating equations and
SAS Proc Genmod software.27
We adjusted for all known and suspected confounders of
the relationship of baseline vitamin D levels with the out-
comes.28 These included age, CD4 cell count at baseline,
height, and education levels for the wasting outcomes and
age, HIV disease stage, CD4 cell count, BMI, primiparity,
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anemia (Hb < 7.0 g/dL), and erythrocyte sedimentation rate
( > 81mm/h) at baseline, and multivitamin regime received
for the comorbidities. Observations with missing data for
covariates were retained in the analysis using the missing
indicator method for variables missing greater than 1% of the
observations.29 Statistical analyses were performed using SAS
software version 9.2 (SAS Institute Inc., Cary, NC).
Results
The baseline characteristics of the 884 women participating
in the trial of vitamin supplementation, who had information
on vitamin D status at enrolment, are presented in Table 1.
There were no major differences in sociodemographic char-
acteristics such as age, WHO HIV disease stage, CD4 T-cell
counts, BMI, or hemoglobin concentrations between women
with insufficient levels of vitamin D and women with ade-
quate vitamin D status. The mean (standard deviation) serum
25-hydroxyvitamin D concentration in women classified as
having insufficient vitamin D was 24.2 (6.2) ng/mL and in
womenwith adequate vitamin D status was 43.1 (9.4) ng/mL.
In the results from the analysis examining the relationship
between vitamin D status and wasting outcomes during a
median of 70 months of follow-up, a total of 222 women ex-
perienced an episode of wasting as defined by BMI less than
18 kg/m2 during follow-up. More than 500 women experi-
enced aweight loss of more than 10%during follow-up. There
was no significant relationship between low vitamin D status
and any of the wasting outcomes, when the complete dura-
tion of follow-up was included in the analysis (data not
shown).
In Table 2, we restricted the analysis to the first 2 years of
follow-up and observed that low vitamin D status was asso-
ciatedwith a significantly increased risk of wasting defined as
BMI less than 18 kg/m2 (hazard ratio [HR]: 1.43; 95% confi-
dence intervals [CI]: 1.03, 1.99; p value: 0.03). Notably, 145
women experienced an episode of wasting in the first 2 years
of follow-up, of the total 222 women who experienced such
an event in the complete duration of follow-up. In analysis
with continuous vitamin D levels using restricted cubic
splines, we found that risk of wasting during the first 2 years
of follow-up was inversely and linearly related to vitamin D
concentrations; the higher the vitamin D levels, lower the risk
of wasting defined as BMI less than 18 kg/m2 (Fig. 1; p: 0.03).
There was no relationship between low vitamin D status
and clinical signs and symptoms during follow-up (Table 3)
Table 1. Baseline Characteristics of Women Enrolled in the Trial with Available Vitamin D Levels (n = 884)
Low vitamin D
(n = 347)
Adequate vitamin D
(n = 537)
Variable
Mean – SD or
frequency (%)
Mean – SD or
frequency (%)
Age
Less than 20 years 45 (12.97) 71 (13.22)
20–24 years 144 (41.50) 213 (39.66)
25–29 years 105 (30.26) 166 (30.91)
Greater than or equal to 30 years 53 (15.27) 87 (16.20)
WHO HIV stage
I 278 (80.12) 457 (85.10)
II 60 (17.29) 75 (13.97)
III 9 (2.59) 5 (0.93)
CD4 category, cells/lL 413.45 – 202.32 428.65– 210.14
Body Mass Index (BMI), kg/m2 23.01 – 3.20 23.39– 3.20
Height, cm 156.48 – 5.86 156.86– 5.94
Mid–upper arm circumference (MUAC), cm 25.37 – 2.85 25.67– 2.85
Hemoglobin at baseline, g/L 93.50 – 17.29 95.25– 16.70
Vitamin D [Serum 25(OH)D] at baseline, ng/mL 24.22 – 6.16 43.07– 9.40
SD, standard deviation.
Table 2. Wasting Outcomes and Low Vitamin D Status: First 2 Years of Follow-Up
Low vitamin D
Yes
n (N)
No
n (N)
Univariate Multivariatea
Outcome RR (95% CI) p Valueb RR (95% CI) p Valueb
BMI < 18 kg/m2 65 (330) 80 (521) 1.42 (1.02, 1.96) 0.04 1.43 (1.03, 1.99) 0.03
MUAC < 22 cm 68 (313) 108 (501) 1.05 (0.78, 1.43) 0.73 1.04 (0.77, 1.41) 0.80
Weight loss > 10% 165 (336) 275 (527) 1.02 (0.84, 1.24) 0.84 1.02 (0.84, 1.24) 0.82
aAll multivariate models adjusted for age, CD4 cell counts at baseline, height, and education levels.
bp Values from Cox proportional hazards regression models.
Low vitamin D status was defined as serum 25-hydroxyvitamin D concentrations< 32ng/mL.
BMI, body mass index; MUAC, mid–upper arm circumference; RR, Incidence rate ratio.
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except for acute upper respiratory tract infection (relative risk
[RR]: 1.18; 95% CI: 1.03, 1.37; p value: 0.02). When we re-
stricted the analysis to the first 2 years of follow-up (Table 4),
we found that low vitamin D status was significantly associ-
ated with increased risks of thrush (RR: 2.74; 95% CI: 1.29,
5.83; p value: 0.01), in addition to acute upper respiratory tract
infection.
Discussion
While there are an increasing number of studies being
published about HIV-infected patients having inadequate
concentrations of vitamin D,30–36 there is limited literature on
the association of low vitamin D status with long-term clinical
outcomes. In previous work in the same cohort, we have
shown that low vitamin D levels are associated with increased
risk of HIV disease progression, anemia, and mortality.13 In
this study, we observed that low vitamin D status is associated
with increased risk of HIV-related complications including
wasting (BMI< 18 kg/m2), thrush, and acute upper respiratory
tract infections through the first 2 years of follow-up.
Wasting is a hallmark of HIV disease in adults22,23 and is
associated with adverse HIV-related health outcomes and
survival.37 For example, in a study in the Gambia, a BMI of
less than 18 kg/m2 was associated with a more than twofold
increase in risk of mortality.20 BMI and changes in weight also
determine the clinical stage of HIV disease and affect timing
and initiation of antiretroviral therapy.38–41 The etiology of
wasting is complex and includes the increased secretion of
pro-inflammatory cytokines including tumor necrosis factor-a
(TNF-a), interferon-gamma (INF-c), and interleukins (IL) 1
and 6.42,43 Both TNF-a and INF-c are known to inhibit myosin
expression in muscle cells,44 and TNF-a also induces anorex-
ia.45 A potential explanation of the observed association
between vitamin D and wasting may be the known anti-
inflammatory role of Vitamin D that includes decreasing the
levels of TNF-a.46–52
Vitamin D is also a known immunomodulator and is ex-
tensively involved in both innate and adaptive immunity.1
Vitamin D is needed for induction of cathelicidin, an antimi-
crobial peptide, which is responsible for intracellular killing of
pathogens such asMycobacterium tuberculosis.5 Vitamin D also
induces autophagy in infected macrophages.53 These effects
on the immune system may explain the relationship of low
vitaminD levels with increased risk of thrush and acute upper
respiratory tract infections observed in this study.
FIG. 1. Association of vitamin D status with wasting (body
mass index [BMI] < 18 kg/m2) in the first 2 years of follow-
up. Adjusted for baseline age, CD4 T-cell count, height, and
education levels.
Table 3. Vitamin D and HIV-Related Complications Among Women During Follow-Up (n = 884)
Complication
Episodes
mean (SD)a
Relative risk for
low vitamin D (95% CI)
p
Valueb
Adjusted relative risk for
low vitamin D (95% CI)c
p
Valueb
Thrush 0.15 (0.50) 0.99 (0.70, 1.41) 0.96 0.94 (0.66, 1.34) 0.74
Acute upper respiratory tract infection 0.85 (1.19) 1.18 (1.02, 1.36) 0.02 1.18 (1.03, 1.37) 0.02
Reported mouth and throat ulcers 0.29 (0.98) 1.15 (0.86, 1.56) 0.34 1.05 (0.77, 1.44) 0.74
Painful tongue or mouth 0.32 (1.03) 1.07 (0.80, 1.43) 0.66 0.97 (0.71, 1.32) 0.83
Difficult or painful swallowing 0.16 (0.56) 1.06 (0.77, 1.46) 0.74 1.04 (0.74, 1.47) 0.83
Nausea and vomiting 0.36 (1.03) 1.06 (0.82, 1.36) 0.66 1.03 (0.79, 1.34) 0.83
Diarrhea 0.54 (1.20) 0.92 (0.73, 1.16) 0.50 0.91 (0.72, 1.14) 0.40
Dysentery 0.18 (0.63) 0.77 (0.56, 1.05) 0.10 0.77 (0.57, 1.03) 0.08
Fatigue 0.60 (1.42) 1.26 (1.00, 1.58) 0.05 1.15 (0.92, 1.45) 0.21
Rash 0.98 (1.77) 1.09 (0.88, 1.34) 0.43 1.04 (0.84, 1.28) 0.73
aMean number of episodes per year per woman (the average number of episodes per visit*12). Low vitamin D status was defined as serum
25-hydroxyvitamin D concentrations < 32 ng/mL.
bp values from Generalized Estimating Equations using Proc Genmod in SAS.
cAll multivariate models adjusted for age, HIV disease stage, CD4 cell count, BMI, primiparity, anemia (Hb< 7.0 g/dL), and erythrocyte
sedimentation rate ( > 81mm/h) at baseline, and multivitamin regime received.
SD, standard deviation; CI, confidence interval; BMI, body mass index.
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In summary, in addition to decreasing the risk of HIV
disease progression, anemia, and mortality, vitamin D levels
are associated with decreased incidence of HIV-related
complications such as wasting and opportunistic illnesses.
The findings of our study need to be confirmed in the setting
of a randomized controlled trial; if found to be effective,
vitamin D supplementation may be a potential adjunct
treatment to antiretroviral therapy to ameliorate HIV-related
complications and improve the quality of life of HIV-infected
patients.
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